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Abstract
Background: The omics fields promise to revolutionize our understanding of biology and biomedicine. However, their 
potential is compromised by the challenge to analyze the huge datasets produced. Analysis of omics data is plagued 
by the curse of dimensionality, resulting in imprecise estimates of model parameters and performance. Moreover, the 
integration of omics data with other data sources is difficult to shoehorn into classical statistical models. This has 
resulted in ad hoc approaches to address specific problems.
Results: We present a general approach to omics data analysis that alleviates these problems. By combining eScience 
and Bayesian methods, we retrieve scientific information and data from multiple sources and coherently incorporate 
them into large models. These models improve the accuracy of predictions and offer new insights into the underlying 
mechanisms. This "eScience-Bayes" approach is demonstrated in two proof-of-principle applications, one for breast 
cancer prognosis prediction from transcriptomic data and one for protein-protein interaction studies based on 
proteomic data.
Conclusions: Bayesian statistics provide the flexibility to tailor statistical models to the complex data structures in 
omics biology as well as permitting coherent integration of multiple data sources. However, Bayesian methods are in 
general computationally demanding and require specification of possibly thousands of prior distributions. eScience 
can help us overcome these difficulties. The eScience-Bayes thus approach permits us to fully leverage on the 
advantages of Bayesian methods, resulting in models with improved predictive performance that gives more 
information about the underlying biological system.
Background
High-throughput experimental methods, including DNA
and protein microarrays and other omics techniques,
have become ubiquitous, indispensable tools in biology
and biomedicine. The number of high-throughput tech-
nologies is constantly increasing. They provide the power
to measure thousands of features of a biological system in
a single experiment, and they have the potential to revo-
lutionize our understanding of biology and medicine.
However, the high expectations for omics methods have
fallen short of realization, due to the challenges the data
present for statistical modeling. Thus, the wealth of data
produced is difficult to translate into concrete biological
knowledge, new drugs, and clinical practices [1,2]. A
recurring problem is that few experimental samples are
generated relative to the number of model parameters [1].
This leads to imprecise parameter and performance esti-
mates, and models prone to overfitting (the 'curse of
dimensionality'). In fact, it is difficult to even obtain a
trustworthy measure of how imprecise performance esti-
mates are with standard techniques like confidence inter-
vals based on holdout estimates in cross-validation or
bootstrapping [3,4]. Another problem is that classical sta-
tistical models are too restrictive to account for the com-
plexities of integrating omics data with previously
a c q u i r e d  d a t a .  T h i s  h a s  f o r c e d  u s  t o  r e s o r t  t o  ad hoc
approaches for solving very specific problems [5-7]. Sta-
tistical approaches that use prior distributions over the
model parameters are known as Bayesian methods [8,9].
The prior distributions summarize one's belief about the
parameters before seeing the data. After performing an
experiment, the parameters are updated to a posterior
distribution according to Bayes' theorem:
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The posterior distribution reflects the contribution of
both our prior beliefs and the experimental data (through
the likelihood function).
Bayesian methods have a number of advantages that
allow us to address the problems inherent in omics data
analysis. Firstly, they afford formal and coherent incorpo-
ration of prior information and integration of data
sources. Apart from the philosophical appeal of being
able to use all available information when analyzing a
problem, this allows us to tackle the curse of dimension-
ality in two ways: (1) Prior information can be used to
reduce model dimensionality with Bayesian variable
selection and regularization, and (2) data from different
research studies can be coherently combined to increase
the number of available observations. Bayesian modeling
thus allows us to "borrow information" across studies [8].
Secondly, Bayesian methods correctly summarize the
model's predictive distribution [10]. Thus, we can obtain
reliable Bayesian confidence intervals (often called credi-
ble intervals) of the estimates of model performance in
small-sample problems; this avoids the problem of having
to rely on imprecise confidence intervals based on hold-
out estimates from cross-validation or bootstrapping [4].
Thirdly, Bayesian methods may be applied to problems
with structures too complex for classical statistical meth-
ods [11]. Bayesian models can be made increasingly elab-
orate to accommodate for the integration of prior
information and omics data from multiple data sources.
However, the advantages of Bayesian modeling come at
a price. We have to specify prior distributions for all
parameters in a model. For large models, like those for
analyzing omics data, it is unrealistic to expect practitio-
ners to manually collect prior information for all individ-
ual parameters. In practice, this limits the powerful
advantage of using available prior knowledge. In addition,
Bayesian methods require numerical handling of analyti-
cally intractable integrals. This is typically performed
with Markov chain Monte Carlo (MCMC) methods,
which are computationally very expensive and therefore
restricts the size of the modeling problems that we can
address.
Recent developments in distributed information and
computational resources have given rise to the notion of
eScience, i.e. computationally intensive science that is
carried out in highly distributed network environments
[12]. Advances in eScience can be roughly grouped into:
(1) developments in semantic technologies (e.g. data
standardization and ontologization) and methods for
retrieving standardized data (e.g. Web services); and (2)
construction of high-performance computing (HPC)
facilities and development of middleware for using the
HPCs. These two aspects of eScience equip us for effi-
cient use of the Bayesian approach to omics data analysis.
Standardized data and Web services allow us to use
machines to harvest the Internet for information to use in
prior distribution specifications, and HPC resources pro-
vide the computational power required to fit large Bayes-
ian models to high-throughput data (Fig. 1). In this paper
we demonstrate how eScience permit us to leverage on
the advantages of Bayesian analysis when modeling omics
data. W e show by two examples that the approach can
improve predictive performance, and that it permits a
deeper analysis of the data by accommodating more com-
plex model structures.
Results
Transcriptomics data: Predicting distant metastasis 
development in breast cancer patients
Microarray gene expression profiling has shown promise
for supporting the prognostication of breast cancer
patients based on the expression pattern of specific gene
sets ('signatures'). A number of studies have reported dif-
ferent signatures [13-16]. However, concerns have been
raised against the prognostic capacity of these signatures
when applied to new data [17,18]. These concerns include
the following:
posterior likelihood prior ∝⋅
Figure 1 The eScience-Bayes approach. The red blocks represent 
the two aspects of eScience discussed in the main text: (light red) 
structured, federated, stored data and information that is retrievable 
with machines, and (dark red) networked computational power. The 
blue block represents the Bayesian part of the work flow: data setup 
and specification of the statistical model. The green blocks represent 
that locally produced data and information can be used together with 
the data and prior information retrieved from the Internet. (A) Interop-
erable machine-to-machine interactions, e.g. Web services, are em-
ployed to search the Internet for available information and data related 
to the biological or biomedical problem under study. (B) The biologi-
cal or biomedical system is described in a Bayesian statistical model. 
The information collected in (A) is used to derive prior distributions of 
the parameters in the model, which summarize our a priori knowledge 
about the system. The data retrieved in (A) combined with any locally 
available data is used to update the prior distributions to a posterior 
distribution via the likelihood function (which represents the contribu-
tion of the data to the posterior distribution). (C) Fitting all but the sim-
plest Bayesian models requires numerical integration, which is 
computationally highly demanding. Deploying the numerical integra-
tion on a HPC facility enables fitting large models in a manageable 
time.Eklund et al. BMC Bioinformatics 2010, 11:282
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1. Signatures from different studies share almost no
genes, which indicates that the signatures depend to a
large degree on the datasets rather than being prog-
nostic for breast cancer [17]. In fact, Michiels et al.
[18] showed that, even within a study, the subset of
patients used for signature derivation strongly influ-
enced which genes were selected.
2. The reported performance estimates of the signa-
tures have been questioned [18]; this suggests that
worse performance is likely to be obtained when
applied to new data. Also, the confidence intervals of
the performance estimates (if reported at all) have
been disputed [4,18]. This makes it difficult to assess
the level of accuracy in the reported results.
In fact, both these concerns arise due to the small sam-
ple sizes typically used in microarray studies relative to
the number of profiled genes (i.e. the curse of dimension-
ality). We employed the eScience-Bayes strategy
described in Fig. 1 to address this problem. In accordance
with the practice in most previous articles, we modeled
the development of distant metastases within five years.
To increase the sample size, we used the Gene Expression
Omnibus (GEO) Web service [19] to collect data from
five previously published breast cancer studies [13-16,20].
To reduce the model dimensionality we employed a
Bayesian variable selection procedure, giving higher prior
probabilities of including a variable (gene) the higher our
prior belief that the gene affects development of distant
metastases. The prior belief for each gene to affect devel-
opment of distant metastases was based on information
retrieved by connecting three Web services: NetPath
http://www.netpath.org/, DictService http://ser-
vices.aonaware.com/ and Entrez Utilities http://
eutils.ncbi.nlm.nih.gov/entrez/eutils/soap/v2.0/DOC/
esoap_help.html. NetPath is a curated resource of genes
reported to be transcriptionally regulated by cancer-sig-
nalling pathways. All genes on the HG-U133A array listed
in NetPath were used to text mine PubMed for all free
fulltext articles where the gene names were mentioned in
combination with breast cancer. To reduce the number of
spurious hits, we discarded genes with names that repre-
sent English words by using the dictionary definition Web
service DictService. This gave us a list of integers, associ-
ated with the genes on the HG-U133A array representing
the number of times a cancer-pathway regulated gene is
mentioned together with breast cancer in the literature
(all genes not present in NetPath were assigned the num-
ber 0). These informative prior distributions were thus
based on the assumption that the probability of a gene
being related to breast cancer was reflected in the num-
ber of times a gene reported in NetPath was mentioned in
combination with breast cancer in PubMed articles. A
work flow of the procedure is shown in Fig. 2 (further
details are given in Methods). The five datasets and the
prior distributions were incorporated in a multilevel
Bayesian probit model (Model I, see Methods). To assess
the discriminative power of Model I, we fitted it five
times; each time using three of the datasets as training
sets and the remaining two datasets as independent
testsets (Fig. 3a, red curve, and b; Additional file 1, Fig. S1
and S2; Table S1). It may be noted that Model I achieved
high prediction accuracy on independent test data pro-
duced in different research groups. To the best of our
knowledge, this is the first time that a modeling approach
has demonstrated consistently good predictive ability
across multiple independent testsets for predicting breast
cancer metastasis development from gene expression
data.
To validate the value of using prior information, we
tested Model I with non-informative prior distributions
(i.e. we assigned equal prior probability for all variables to
be included in the variable selection; see Methods for fur-
ther details) and compared the results to those obtained
with informative priors (Fig. 3a, green curve; Additional
file 1, Fig. S1, green curves; Table S1). This clearly showed
that the use of relevant prior information significantly
improves the classification accuracy of Model I (Bayesian
P-value < 0.001, related to the curves in Fig. 3a). The dra-
matic improvement was due to the fact that the prior
Figure 2 eScience-Bayes applied to microarray gene expression 
data. Illustration of using the eScience-Bayes approach to model time 
to development of distant metastases in breast cancer patients from 
microarray gene expression data. (Color-coding is as in Fig. 1; the green 
blocks in Fig. 1 are not included since we did not use any locally pro-
duced data or information.) (A) We downloaded five breast cancer 
gene expression datasets and their associated clinical data using the 
Gene Expression Omnibus (GEO) Web service. For trustworthy prior in-
formation about genes with altered transcriptional regulation in breast 
cancer patients, we used three Web services in conjunction: NetPath, 
DictService and Entrez Utilities. This gave us a list of integers that rep-
resented the number of times a cancer-pathway regulated gene on 
the HG-U133A array was mentioned in PubMed articles together with 
breast cancer. (B) We used the prior information derived in (A) to re-
strict the dimensionality of Models I and II by Bayesian variable selec-
tion. We did this by deriving prior distributions based on the 
assumption that the probability of a gene being related to breast can-
cer was reflected in the number of times a gene reported in NetPath 
was mentioned in combination with breast cancer in PubMed articles. 
(C) The models were fit by performing calculations a HPC resource.Eklund et al. BMC Bioinformatics 2010, 11:282
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information focused the model to include relevant genes
in the signature, thus reducing the risk of detecting spuri-
ous relationships and overfitting the model. Analogously,
the use of prior information enforced consistency in sig-
nature selection across disparate datasets: 15.2% of the
genes were selected all five times Model I with informa-
tive priors was fit, which may be compared to 1% when
noninformative priors were used, and 0% among the orig-
inal signatures. The median of the pairwise overlap
between two different model fits was 27.5%, compared to
3% among the original signatures and 12% reported in
Chuang et al. [6].
Figure 3 Model I and II results. ROC curves and Kaplan-Meier (KM) curves produced with Model I and II (data from Desmedt et al. [20], Miller et al. 
[14], and Sotiriou et al. [15] was used for training, and the data from Wang et al. [13] and Pawitan et al. [16] for testing). Solid lines show the mode of 
the curves? distributions; dotted lines show the 95% Bayesian confidence intervals. (A) ROC curves for Model I. Red and green lines represent Model 
I results after training on multiple datasets with informative and noninformative priors, receptively. Blue lines represent Model I after training on a sin-
gle dataset. The area under the curves (AUC) are 0.76 (0.71; 0.80), 0.57 (0.55; 0.58), and 0.51 (0.44; 0.60), respectively (numbers in parentheses show the 
Bayesian confidence intervals). The predictive performance of Model I trained with multiple datasets and informative priors was found to be signifi-
cantly better than when using noninformative priors and with only a single dataset for training (Bayesian p-value < 0.0005 in both cases). (B) KM curves 
[44] for patients predicted by Model I (at 80% specificity) indicate the probability that patients develop distant metastases before (red) and after (cyan) 
5 years. (C) Survival times predicted by Model II. The KM curves show survival of patients belonging to the predicted percentiles 0-33, 34-66, 67-100 
(red, green, and red curves, respectively). The difference between the three groups is significant (Bayesian P-value < 0.003).Eklund et al. BMC Bioinformatics 2010, 11:282
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We also assessed the advantage of using multiple data-
sets by using only single datasets for training Model I
(with informative priors); results are shown in Fig. 3a
(blue curve), Additional file 1, Fig. S1 (blue curves) and
Table S1. A significant improvement was found when
multiple datasets were used for model training compared
to when only a single dataset was used (Bayesian P-value
< 0.001, related to the curves in Fig. 3a). In a final com-
parison, we modified Model I to use only the expression
data that corresponded to the respective gene signatures
derived in Wang et al. [13], Miller et al. [14], Sotiriou et
al. [15], and Pawitan et al. [16], together with noninfor-
mative priors (only the genes printed on the HG-U133A
were used for the Miller et al. [14] and Pawitan et al. [16]
signatures). Again, we found that Model I (with informa-
tive priors) performed significantly better than when the
signatures from Wang et al. [13], Miller et al. [14],
Sotiriou et al. [15], and Pawitan et al. [16] were used.
Results are displayed in Additional file 1, Fig. S4 and
Table S1. To derive a "final" gene signature, we fitted
Model I using all five datasets and informative priors.
Some genes were included in this signature that a priori
had been regarded as non-relevant to breast cancer; these
genes were strongly supported by the data and may be of
interest for future experimental investigations. The genes
included in the signature are shown in Additional file 1,
Table S2, stratified into genes that were relevant a priori
as well as a posteriori, and genes that were regarded non-
relevant a priori but relevant a posteriori.
In order to further demonstrate the eScience-Bayes
approach, we used it to create a model that predicted the
probability of distant metastasis development as a func-
tion of time. This model would provide finer granularity
in the prognosis predictions of future patients compared
to the current practice of stratifying patients into only
two classes (metastases or no metastases within five
years). Patient stratification into two classes discards
information by discretizing a continuous variable (time to
development of distant metastasis) into an arbitrarily
defined binary variable (yes/no development of distant
metastasis within five years). Because not all patients had
developed distant metastases before the last follow-up in
the studies, this required a consideration of the censoring
of the data (Methods). We created a multilevel Bayesian
accelerated failure time (AFT) (Methods; Sha et al. [21])
model with the expression data as explanatory variables
and the informative prior distributions (Model II, see
Methods for details). Analogously to the assessment of
Models I, we assessed Model II by fitting it five times,
each time using three of the datasets as a training set and
the remaining two datasets as test sets to assess the per-
formance of Model II. The results implied that we indeed
could provide more fine-grained prognoses predictions,
compared to the binary classification afforded with
Model I (Fig. 3c).
In this example, we provided evidence for that adopting
the eScience-Bayes approach can significantly improve
consistency in gene signature selection and in the predic-
tive performance of the constructed models. In contrast
to previous studies, our results were presented together
with Bayesian confidence intervals, which permit assess-
ment of the level of accuracy in the results [4].
Proteomics data: Analyzing PDZ domain-peptide 
interactions
PDZ domains mediate protein-protein interactions and
have been extensively studied over the last fifteen years.
Recently, a large-scale PDZ domain-peptide interaction
dataset was published in Stiffler et al. [22] and follow-up
studies were later described in Chen et al. [23]. The com-
bined data from these two publications comprise 2306
observations of interactions between peptides and PDZ
domains from mouse, C. elegans, and D. melanogaster.
We reanalyzed these data using the eScience-Bayes
approach. To this end, we modeled the PDZ domain-pep-
tide interactions using a multilevel Bayesian probit model
with physicochemical properties of the PDZ domains and
peptides as explanatory variables and a binary variable as
response, indicating whether or not a PDZ domain and a
peptide bound to each other (Model III). We derived
informative prior distributions from 3D structural infor-
mation using the Sequence Annotated by Structure [24]
(SAS), a tool for annotating a protein sequence with
structural information based on all solved 3D structures
of the proteins in the Protein Data Bank [25] (PDB).
Using the SAS Web service [26] (WSsas) we estiamted
the number of contacts made between residues in each
PDZ domain and in the peptide ligands. Similarly to the
breast cancer demonstration, we used the informative
prior distributions to "guide" the variable selection in
order to reduce the dimensionality of the model based on
the assumption that the importance of a PDZ domain res-
idue for the interaction is reflected in the number of con-
tacts it makes with the ligand (see Methods for details).
Fig. 4 shows the work flow for the prior elicitation and
modeling. Fig. 5a summarizes the predictive performance
of Model III in a receiver operating characteristics (ROC,
see Methods) curve based on a 10-fold cross-validation,
and shows a comparison with the predictive performance
when noninformative prior distributions were used (i.e.
equal prior probability for all variables to be included in
the variable selection; see Methods). We observed a non-
significant (Bayesian P-value = 0.11) improvement in the
predictive performance with informative compared to
noninformative priors (Fig. 5a).
In this example, the main advantage of adopting an
eScience-Bayes approach was the increase in informationEklund et al. BMC Bioinformatics 2010, 11:282
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that we obtained. For example, Model III enabled an anal-
ysis of the differences between PDZ domains. By allowing
the regression coefficients to vary between PDZ domains
(Methods), we found differences in the estimated non-
zero coefficients for different PDZ domains (Fig. 5b). This
suggests that there may be variations among the PDZ
domains in the networks of residues that are important
for interacting with ligands [27]. Interestingly, some of
these residues are located far away from the binding site.
Although the tertiary structures of PDZ domains are very
similar, their primary structures vary substantially [28].
This may cause differences in the intramolecular interac-
tions within different PDZ domains. Networks of such
intramolecular interaction have previously been reported
for PDZ domains [28,29]. The results from studies by
Gianni et al. [29] and Chi et al. [30] support the notion
that the networks may differ among PDZ domains; for
example, a network present in a PDZ domain from mouse
tyrosine phosphatase BL was not found in the human
PSD-95 PDZ3. The eScience-Bayes approach allowed
analysis of these differences across a large set of PDZ
domains.
Model III further indicated that the PDZ domains from
C. elegans and D. melanogaster may form two clusters
(Fig. 5b). Given the small datasets from C. elegans and D.
melanogaster, which contain only seven PDZ domains
each (Fig. 4), the clustering might be a sampling or an
experimental artifact. Nevertheless, it is tantalizing to
hypothesize that there are general trends in the intramo-
lecular interaction networks in PDZ domains that differ
between species. These observed differences are further
illustrated in Fig 5c, where five residues, estimated to be
allosterically linked to residues in the binding peptide, are
shown in one representative PDZ domain from mouse, C.
elegans, and D. melanogaster. As shown in the figure, dif-
ferent amino acids, with different positions and physico-
chemical properties, are estimated to be allosterically
coupled to the binding peptide in the three different PDZ
domains.
This example shows that an eScience-Bayes approach
to modeling omics data can straightforwardly accommo-
date grouping structures in the data. This enables the
analysis to reveal tentative differences among PDZ
domains that allowed the inference of putative allosteric
networks.
Discussion and Conclusions
In a recent Nature Horizons article [12], Cambridge
chemistry professor Peter Murray-Rust sketched an
eScience world where the answer to any question is at the
fingertips of every person; the complexity of the question
and the size of the data to analyze do not matter. Com-
puters perform all trivial and time-consuming tasks, like
searching through millions of research articles or per-
forming massive algorithmic calculations. In this proof-
of-principle paper we have shown that some aspects of
this vision in fact have been realized: machines can via
Web services be used to retrieve background information
that together with multiple data sources (produced
locally or retrieved from the Internet) can be coherently
exploited in a Bayesian framework to create complex
models by employment of HPC resources, thus allowing
us to provide answers to biologically relevant questions.
This  modus operandi contrasts to non-Bayesian
approaches for merging multiple omics datasets and for
integrating omics data with prior information, which to a
large degree have relied on ad hoc methods for solving
specific problems (see e.g. Kutalik et al. [5], Chuang et al.
[6], and Xu et al. [7]). Bayesian statistics provide the flexi-
bility to tailor statistical models to complex data struc-
tures, and can simultaneously accommodate prior
information. The rather complex models described here
would be diffcult to fit using classical statistics. We dem-
onstrated the value of the Bayesian approach with the
quite drastic improvements in prediction accuracy in the
breast cancer example, and the enhanced depth of the
data analysis in the PDZ domain-peptide interaction
example. However, presently the eScience-Bayes
approach is not easy to apply because it requires manual
procurement of suitable information resources and Web
services, and it requires programming skills to implement
the Web service clients, parse the output, and connect
them together. Moreover, the eScience-Bayes approach
Figure 4 eScience-Bayes applied to protein-protein interaction 
data. Modeling of the PDZ domain-peptide interaction data with the 
eScience-Bayes approach. (Color-coding is as in Fig. 1.) (A) All PDZ and 
peptide sequences and interaction data were retrieved from the sup-
plementary material of Chen et al. [23] via PubMed Central. The PDZ se-
quences were aligned using the MUSCLE Web service. Prior 
information was retrieved using the SAS Web service. SAS was used to 
determine the number of contacts made between PDZ domain resi-
dues and ligand residues from the 3D complexes available in the Pro-
tein Data Bank. (B) The aligned PDZ domain and peptide sequences 
were characterized by numbers capturing their physicochemical prop-
erties. The characterizations of the PDZ domain-peptide interactions 
were correlated to a 1 or a 0 in a binary response variable, which indi-
cated whether a PDZ domain and a peptide could bind or not to each 
other. Analogous to the breast cancer demonstration, we reduce the 
dimensionality of the model guided by the prior information derived 
in (A) (see Methods). (C) The models were fit on an HPC resource.Eklund et al. BMC Bioinformatics 2010, 11:282
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requires implementation of MCMC-algorithms to fit
Bayesian models and knowledge of middleware and non-
user-friendly interfaces for deployment of the MCMC-
algorithms on HPC facilities. However, the most crucial
difficulty is the prior elicitation process. Since the prior
distributions are central in the Bayesian paradigm, a key
aspect of applying the eScienceBayes approach is to sum-
marize retrieved prior knowledge as distributions. In
both the breast cancer and PDZ domain demonstrations
we used prior information quantified as integers to repre-
sent our a priori belief of the independent variables rele-
vance for modeling the response. Although care was
taken to design the prior distributions in a sensible way,
the prior specifications reflects a somewhat arbitrary step
in the work flow, and there is presently no clear way to
standardize prior elicitation and make the process trans-
parent, exchangeable, and completely general. Related to
t his  diffi cult y , a no t he r  pr o ble m  is  t ha t  use ful da ta a nd
prior information in today's scientific practice are lost in
objects that are inaccessible to computers, such as fig-
ures, tables, and summary statistics.
Figure 5 Model III results. (A) The ROC curves for Model III; the red and blue lines show the results when the prior information was or was not used, 
respectively. Solid lines denote the mode of the ROC curve distribution, and the dotted lines the 95% Bayesian confidence intervals. The area under 
the curves (AUC) are 0.92 (0.89;0.93) (red) and 0.90 (0.87;0.92) (blue). (B) Trends in differences between different PDZ domains were obtained by al-
lowing the regression coefficients to vary with PDZ domains, and then subjecting the resulting matrix of regression coefficients to a principal compo-
nent analysis (PCA) and plotting the PDZ domains in the space of the first three principal components. It should be noted that the regression 
coefficients are evenly distributed, which supports the relaxation of the canonical PDZ classes proposed in e.g. Stiffler et al. [22] and Tonikian et al. [37]. 
The regression coefficients from interactions in C. elegans (green dots) and D. melanogaster (blue dots) cluster together in the outskirts of the mouse 
interactions (red dots).(C) Differences in predicted networks between different PDZ domains. Five residues (spacefilled) located outside the binding 
pocket that were estimated with Model III to be allosterically linked to residues in the binding peptide (light green) in representative PDZ domains: (i) 
mouse α1-syntrophin(1/1), (ii) D. melanogaster Lap4(2/4), and (iii) C. elegans Lin7(1/1). The network residues are color coded according to the physic-
ochemical property that is estimated to be important for the network: blue = size; red = polarity.Eklund et al. BMC Bioinformatics 2010, 11:282
http://www.biomedcentral.com/1471-2105/11/282
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Thus, there is a distinct need for a standardized system
of technologies and tools for working efficiently with
computer representations of biological entities, data,
information, probabilities, and statistical models - both
locally and on the network. Great efforts are indeed being
made in this direction. These include the increasing
degrees of semantically annotated data that are deposited
in public repositories in machine readable formats [31],
new Web service protocols that allow for service discov-
ery [32], semantic web technologies to adhere informa-
tion with probability distributions that can be directly
used as priors in Bayesian statistical models [33], and
high-level languages for specifying fast implementations
of MCMC algorithms [34]. Moreover, graphical work-
benches, like Bioclipse [35], aim to handle all these tasks
from a single point of entry. When these technologies and
software have matured, it will be straightforward to adopt
an eScience-Bayes approach to virtually any biological or
clinical question. It would then be easy to obtain prior
information and data by performing semantic queries, for
example, "give me all breast cancer susceptibility genes
and the probability distributions describing their associa-
tion with increasing risk of distant metastasis develop-
ment, together with all breast cancer Affymetrix HG-
U133A datasets where distant metastasis development
was the clinical end-point". The retrieved priors and data
could then be used directly in a Bayesian statistical model
specified in a high-level language and converted to an
algorithmic fitting process deployed on an HPC facility.
Finally, the results could be summarized graphically to
increase the likelihood of making correct clinical prog-
nostic and treatment decisions.
Methods
Transcriptomics data: Predicting distant metastasis 
development in breast cancer patients
The datasets with accession numbers GSE2034,
GSE7390, GSE4922, GSE2990, and GSE1456 were
retrieved with the GEO Web service [19]. The datasets
were originally published in Wang et al. [13], Desmedt et
al. [20], Miller et al. [14], Sotiriou et al. [15], and Pawitan
et al. [16], and we hence denote them by (X, t, γ)ρ = (Xρ,
tρ, γρ), ρ ￿ {W, D, M, S, P}. X represents gene expression
measurements,  t  the time to development of distant
metastses, and γ is a binary variable indicating censoring.
All five datasets were generated with the Affymetrix HG-
U133A platform and contained measurements of 22283
probes in 286, 198, 166, 189, and 159 patients, respec-
tively (after removal of 85 replicate patients in the (X, t,
γ)M and (X, t, γ)S datasets). The patients in the Miller et
al. [14] and the Pawitan et al. [16] studies were profiled
using both the Affymetrix HG-U133A and HG-U133B
arrays; we here used only the data from the HG-U133A
array. The columns in each Xρ were mean centered and
scaled to unit variance.
We define gj, j = 1,...,22283, to be the gene names of the
probes on the Affymetrix HG-U133A array, and   to be
the set of gene names reported in NetPath as being tran-
scriptionally regulated by cancer pathways, and   to be
the set of words in the English language (Fig. 2). Further,
set hj, j = 1,....,22283, to be the number of free, fulltext
articles in PubMed where the gene name gj was men-
tioned. Finally, let kj, j = 1,...,22283, be defined according
to:
Model I
We modeled whether development of distant metastases
occurred within five years using a multilevel Bayesian
probit model according to:
where  Pr  denotes probability, and Φ is the normal
cumulative distribution function, N the multivariate nor-
mal distribution, δ the one-point distribution, and W-1
the inverse Wishart distribution. nρ denotes the number
of patients in dataset ρ. Jκ is the diagonal matrix with the
non-zero elements in the vector   as diag-
onal elements. Similarly,   and   are the elements of
xρi and βρ, respectively, that correspond to the non-zero
elements in   (xρi relates to patient i  in
dataset ρ and βρ are the regression coefficients related to
dataset ρ). The index ρ indicates that the coefficients var-
ied by breast cancer study (W, D, M, S, P).
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We assumed a priori that on average 100 genes should
be included in the signature (i.e. that   =
100, where E  denotes the expectation operator). This
assumptions was based on the number of genes used in
previously reported signatures [13-16]. Further, we
assumed that the greater the number of times a cancer
pathway regulated gene's name has been mentioned
together with breast cancer in free, fulltext PubMed arti-
cles, the greater is the a priori scientific support that the
gene's regulation is correlated with breast cancer relapse.
Thus, the larger the k-value (as defined in (1)) associated
with a given gene, the greater the a priori probability of
the gene to be included in the signature. In order to give
all genes a chance of being selected, we assign the k-value
1 to a gene not reported in NetPath. Genes reported in
NetPath but not mentioned in any free PubMed article
get the k-value 2. The prior distribution for   is
founded on the idea that the probability of selecting one
variable j of the 22283 variables is proportional to the
variable j's k-value, i.e. Pr(select j in one draw) =  .
Thus, the probability of not  selecting the variable j  is
 and the probability of selecting variable j in m
independent draws is  . All genes thus
have a chance to get selected and all genes have a chance
of not being selected.
Apart from the prior distribution of  , no prior
knowledge was assumed for the remaining model param-
eters (i.e. noninformative priors was used for  , Σκ and
m).
Model I was validated by fitting it five times, each time
using three of the five datasets (X, r, γ)ρ, ρ ￿ {W, D, M, S,
P}, as training sets and the remaining two as independent
test sets. The benefit of using multiple datasets for fitting
Model I was assessed by using the same partitioning of
the five datasets; however this time only one of the three
training sets was used for actually fitting the model (see
Additional file 1, Table S1 for the partitions and results).
The gain of exploiting the prior information was assessed
by modifying Model I so that p = 100/22283 in (2), in
which case all genes get an equal a priori probability to be
included in the signature.
To afford comparisons with the gene signatures pub-
lished in Wang et al. [13], Miller et al. [14], Sotiriou et al.
[15], and Pawitan et al. [16], we modified Model I accord-
ing to:
where   denotes the subset of xρi that corresponds
to the gene signature ρsig derived in publication ρ,   is
the number of genes in the signature ρsig, and   the
identity matrix of rank  .
To derive a gene signature using all the data, we fitted
Model I as described in (2). We counted the number of
times that each gene appeared in the 200,000 draws from
the posterior distribution in the Markov chain Monte
Carlo algorithm (after 200,000 draws burn-in, see below).
We defined the appearance frequency of a gene gj as the
number of appearances of gj divided by the total number
of iterations (i.e., 200,000 here). We reasoned that the
genes with the highest appearance frequencies play the
strongest role in predicting the response. The top 100
genes, according to appearance frequency, were selected
and are found in Additional file 1, Table S2.
Model II
We modeled the time to development of distant metasta-
ses according to:
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where the denotations are as in Model I, and ερi is the
error term for patient i in dataset ρ. Model II was vali-
dated by fitting it five times, each time using three of the
five datasets (X, r, γ)ρ, ρ ￿ {W, D, M, S, P}, as training sets
and the remaining two as independent test sets.
Proteomics data: Analyzing PDZ domain-peptide 
interactions
The peptides and the aligned PDZ sequences (Fig. 4)
were, after removal of alignment positions containing
gaps, converted to numerical vectors capturing the physi-
cochemical properties of each sequence by using the tciz
scales of Muthas et al [36]. The tciz scales are the amino
acids' component scores in the two first principal compo-
nents derived from a principal component analysis of
physicochemical properties of 113 natural and non-natu-
r a l  a m i n o  a c i d s .  T h e  t w o  t c i z  s c a l e s  t h u s  c o d e  e a c h
sequence residue into two real-valued numbers, which
are strongly correlated with the amino acids size and
polarity [36]. The tciz scales thus allow us to numerically
characterize peptides by concatenating the tciz numbers
for all residues in the peptide. Similarly, we could numer-
ically characterize an interaction between a PDZ domain
and a peptide as the concatenated tciz description vectors
of the PDZ domain and the peptide. Characterizing all
interactions in the Stiffler et al. [22] and Chen et al. [23]
datasets gave us a matrix, X, with 2306 observations
(2019 from mouse, 147 from C. elegans, and 140 from D.
melanogaster PDZ domains) and 154 variables (67 resi-
due positions, r1,...,r67, in the alignment of the PDZ
domains were "gap-free", and each position was coded
with two tciz numbers: 67·2 = 134 variables; the peptides
contained 10 residues each: 10·2 = 20 variables).
Let H = (X, H(X)) be mean centered and scaled to unit
variance, where H(X) denotes the second order interac-
tion terms of the variables in X. H thus has 2306 rows and
11935 columns. Let the column vector y = (y1,...,y2306) be
the response variable, where yi = 1 represent that the PDZ
domain and the ligand interact and yi = 0 represents that
they do not interact. We assumed, with support from the
literature [37] and the data from Stiffler et al. [22], that
some PDZ domains are more promiscuous binders than
others. This resulted in a correlated error structure when
m o d e l i n g  t h e  d a t a .  T h i s  i s  a n  a s s u m p t i o n  v i o l a t i o n  i n
standard generalized linear models, but could be accom-
modated for in our Bayesian setting by allowing parame-
ter estimates to vary among PDZ domains. Thus, let ϕ =
1,...,96 denote the 96 PDZ domains in the data from Stif-
fler et al. [22] and Chen et al. [23] (82 from mouse, 7 from
C. elegans, and 7 from D. melanogaster).
The PDZ domain residues r1,...,r67 and the peptide resi-
dues  p1,...,r10  are associated with the integers c1,...,c77,
where the c-values represent the number of contacts its
corresponding residue makes with a ligand, as estimated
by SAS by analyzing all solved 3D structures of PDZ
domain-peptide complexes available in the Protein Data
Bank [25] (PDB) (Fig. 4). We construct the row vectors
where  H(cX) denotes the second order interaction
terms of cX. cX thus represents the c-values of the tciz-
coded residues r1,...,r67 and  p1,...,p10 incremented by 1.
The  c-values were incremented by 1 to ensure that all
variables in H have a chance of being selected (i.e. includ-
ing those with c-values equal to zero).
Model III
We modeled the interaction between PDZ domains and
peptides using a Bayesian hierarchical probit model
according to:
where   is  the  ith row in   (the rows of H corre-
sponding to PDZ domain ϕ). dj is the jth value in the row
vector cX, H(X). Hence, the a priori probability of a variable
to be selected is larger, the larger the number of contacts
the PDZ residue it is derived from makes with the ligand
(the assumption being that the more contact a PDZ resi-
due makes with the ligand, the greater our a priori belief
that the residue is important for the interaction). The
other denotations are analogous to the ones used in
Model I. The prior for m, i.e. the parameter controlling
the number of selected variables, was chosen so that
roughly one twentieth of the total number of variables
was selected (i.e. so that   = 11935/20, where
E  denotes the expectation operator). The mean of the
prior distribution for m was estimated using cross-valida-
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tion on the training data. Model III was also modified to
assess the use of the prior information about which resi-
dues that are important for governing the interaction
between PDZ domains and peptides. We then set p = 1/
11935.
Residue coupling depicted in Fig. 5c
The coupling was estimated by studying the interaction
terms in H formed between tciz scales from one residue
in the PDZ domain and one in the peptide as outlined in
Prusis et al. [38]. The figure displays the five such interac-
tion terms with the largest (absolute-valued) modes of
the regression coefficient's distributions. The network
residues are color coded according to the physicochemi-
cal property that is estimated to be important for the net-
work; residue size is shown in blue and residue polarity in
red. Note that the same PDZ domain 3D structure (α1-
syntrophin PDZ, PDB accession number 2PDZ) has been
used in all three pictures since the structures of Lap4(2/4)
and Lin7(1/1) from C. elegans and D. melanogaster have
not been solved. The residue labels refer to the amino
acid at the given position in Lap4(2/4) and Lin7(1/1) and
do thus not correspond to the structure of the depicted
amino acids. Residue numbering is according to
2PDZ.pdb.
Bayesian P-values
To explain the Bayesian P-values used in the article, we
give the following example: Let   be the two
datasets that were removed when fitting Model I and
 the remaining three datasets. Further, let β
and β' be the regression coefficients when Model I was
fitted with informative and noninformative priors,
respectively. By sampling from the posterior distributions
of  β  and  β', we could estimate the distributions of
 and  . The
Bayesian P-value could then be computed as
. This idea is closely related to the method suggested in
Xiao-Li [39].
ROC curves
ROC curves are plots of the true-positive fraction (TPF)
plotted as a function of the false-positive fraction (FPF)
for a binary classifier system as its discrimination thresh-
old is varied. The TPF and FPF are calculated as follows:
TPF = TP/(TP + FN) and FPF = FP/(FP + TN), where TP
= true positives, FP = false positives, FN = false negatives,
and TN = true negatives. The larger the area under the
curve (the AUC), the better the classifier. The AUC is
equal to the Mann-Whitney U statistic [40], a non-para-
metric test for assessing whether two independent sam-
ples of observations come from the same distribution.
Model fitting
The posterior distributions for Model I, II, and III are not
possible to derive in closed form. The models were thus
fitted using Markov chain Monte Carlo (MCMC) meth-
ods (see Robert and Casella [41] for an excellent account
on MCMC methods). The MCMC algorithms were
implemented in the statistical programming language R
[42]. Three chains were run for each model and after a
burn-in period of 200,000 samples, we collected the fol-
lowing 200,000 samples from the posterior distributions.
Convergence was checked using the potential scale
reduction factor [43]. The computations were performed
on UPPMAX computational resources http://www.upp-
max.uu.se/ under the project p2006026.
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